Faculty profile
Bernhard Eigl
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Chrono-immunotherapy in genitourinary oncology: From emerging evidence to clinical translation (Review).
Oncology letters · 2026
Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.
Scientific reports · 2025
Case report: Two cases of leptomeningeal metastases in patients with metastatic urothelial carcinoma treated with enfortumab vedotin.
Frontiers in oncology · 2024 · senior author
Latest funding
- $1,028,926
Copper Associated Immunogenic Cell Death: Improving the Therapeutic Potential of Immune Check Point Inhibitors for the Treatment of Metastatic Bladder Cancer
CIHR · 2024 · Co-investigator
- $200,000
Active surveillance vs definitive local therapy for patients showing clinical complete response following neoadjuvant cisplatin-based chemotherapy
CIHR · 2023 · Principal investigator
- $841,500
Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer
CIHR · 2021 · Principal investigator
9 publications.
Chrono-immunotherapy in genitourinary oncology: From emerging evidence to clinical translation (Review).
Deen OZ, Ye X, Lee P, Astani R, Bjarnason G, Kollmannsberger C, Eigl B, Ozgun G
Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.
Soleimani M, Thi M, Janfaza S, Ozcan G, Mazurek S, Ozgun G, Maurice-Dror C, Eigl B, Chi K, Kollmannsberger C, Nappi L
Case report: Two cases of leptomeningeal metastases in patients with metastatic urothelial carcinoma treated with enfortumab vedotin.
Fishbein F, Nappi L, Mortazavi B, Eigl B
Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.
Soleimani M, Thi M, Janfaza S, Ozcan G, Mazurek S, Ozgun G, Maurice-Dror C, Eigl B, Chi K, Kollmannsberger C, Nappi L
Small cell carcinoma of the bladder: A population-based analysis of long-term outcomes after radical cystectomy and bladder conservation with chemoradiotherapy.
Oh J, Eigl B, Black PC, Pickles T, Villamil C, Sunderland K, Tyldesley S
Caught in the net: Characterizing how testicular cancer patients use the internet as an information source.
Yeo S, Eigl B, Chan S, Kollmannsberger C, Ingledew PA
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selection.
Black PC, Alimohamed NS, Berman D, Blais N, Eigl B, Karakiewicz PI, Kassouf W, Kulkarni GS, Ong M, Spatz A, Sridhar SS, Stockley T, van der Kwast T, Hew H, Park-Wyllie L, North SA
A fountain of knowledge? The quality of online resources for testicular cancer patients.
Yeo S, Eigl B, Ingledew PA
Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer.
So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M
Copper Associated Immunogenic Cell Death: Improving the Therapeutic Potential of Immune Check Point Inhibitors for the Treatment of Metastatic Bladder Cancer
Principal investigators: Bally, Marcel B; Evgin, Laura E
Keywords: Cancer; Combinations; Copper; Icd-Immunogenic Cell Death; Immune Check Point Inhibitors (Cpis); Immunotherapy; Liposomes; Metal Chemistry; Metastatic Bladder Cancer (Mblc); Small Molecules
Active surveillance vs definitive local therapy for patients showing clinical complete response following neoadjuvant cisplatin-based chemotherapy
Principal investigators: St-Laurent, Marie-Pier; Bell, Keith; Black, Peter C; Eigl, Bernhard J; Noonan, Krista
Keywords: Bladder Cancer; Bladder Preservation; Comparative Effectiveness; Implementation Science; Neoadjuvant Chemotherapy; Radiation Therapy; Radical Cystectomy
Refining the clinical utility of circulating tumour DNA in metastatic bladder cancer
Principal investigators: Wyatt, Alexander W; Eigl, Bernhard J
Keywords: Bladder Cancer; Cancer Genomics; Circulating Tumour Dna (Ctdna); Clinical Outcomes; Metastatic Progression; Treatment Resistance
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Urologic Sciences
- Surgery
- Department of Laboratory Medicine and Pathobiology
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Lucia Nappi
Urologic Sciences
3 shared papers, latest 2025
Kim Chi
Urologic Sciences
2 shared papers, latest 2025
Michael Ong
Faculty
1 shared papers, latest 2020
Tracy Stockley
Department of Laboratory Medicine and Pathobiology
1 shared papers, latest 2020
Martin Gleave
Urologic Sciences
1 shared papers, latest 2008
Wassim Kassouf
Surgery
1 shared papers, latest 2020
Scott Tyldesley
Faculty
1 shared papers, latest 2022
David Berman
Surgery
1 shared papers, latest 2020
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.